Safety evaluation of the canine osteosarcoma vaccine, liveListeriavector

Canine osteosarcoma (OSA) is an aggressive bone tumour in dogs. Standard-of-care treatment typically results in relatively short survival times; thus, alternative treatments are needed to confer a survival advantage. It has been shown that OSA is an immunogenic tumour, suggesting that immune modulation may result in superior outcomes. A cryopreserved,Listeria-based OSA vaccine was recently developed and an initial study in dogs reported prolonged survival for patients receiving the vaccine in conjunction with standard-of-care. The goal of the current observational study was to report on the safety of the lyophilized formulation of this vaccine (the canine OSA vaccine, liveListeriavector [COV-LLV]) in a group of dogs previously diagnosed with OSA. Forty-nine (49) dogs received the COV-LLV and were included for analysis. Adverse events (AEs) noted during and after vaccinations were recorded. The AEs observed were typically mild and self-limiting, with nausea, lethargy and fever being most common. Four dogs (8%) cultured positive forListeria(three infections including an amputation site abscess, septic stifle joint and bacterial cystitis; and one dog whose lungs culturedListeria-positive on necropsy within 24 hours of COV-LLV administration). These cases join the previously reportedListeria-positive thoracic abscess that developed in a canine following use of COV-LLV. Although uncommon, it is important to realize this clinically significant AE is possible in patients treated with live therapeuticListeriavaccines. AsListeriais zoonotic, caution is required not only for the patient receiving the vaccine, but also for the health care workers and family caring for the patient.